尿素毒素与药物之间的载体介导相互作用:慢性病中毒性的隐藏驱动因素
Pierre Spicher1,2, François Brazier1,3, Solène M Laville1,4
1MP3CV Laboratory, UR7517, Jules Verne University of Picardie, F-80000 Amiens, France.
International journal of molecular sciences
|July 12, 2025
概括
慢性病 (CKD) 涉及尿路毒素的积累,如硫酸 (IS) 和p-cresyl硫酸 (PCS). 载体机制影响其消除和潜在的药物相互作用,影响患者管理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 慢性病 (CKD) 导致尿素毒素 (UT) 积累,原因是功能不佳.
- 硫酸 (IS) 和p-硫酸 (PCS) 是关键的尿道,由于高蛋白结合,难以通过透析去除.
研究的目的:
- 审查控制IS,PCS及其前体 (英多尔,p-cresol) 处置的载体介导机制.
- 为了检查这些UT和常见的CKD药物之间的潜在相互作用共享输送通路.
- 突出这些药物毒素相互作用在CKD管理中的临床影响.
主要方法:
- 文献综述侧重于UT处置中的传送器作用.
- 对UT与药物基质/共享载体抑制剂的相互作用进行分析.
- 检查生理障碍:肠道,血脑和脏近道管.
主要成果:
- 载体蛋白质显著影响IS,PCS,英多尔和p-cresol在关键障碍物上的分布和消除.
- 涉及共享载体的药物毒素相互作用可以改变UT的药理动力学和毒性.
- 这些相互作用的了解很少,在临床实践中经常被忽视.
结论:
- 了解传送器介导的尿道处置对于管理CKD患者至关重要.
- 识别药物毒素相互作用可以优化药物治疗并改善患者的治疗结果.
- 需要进一步的研究来描述这些相互作用,以便在多药房环境中更好地做出临床决策.
相关概念视频
01:15Drug Elimination by Renal Route: Tubular Secretion
2.5K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.5K
01:22Drug Elimination by Renal Route: Tubular Reabsorption
3.9K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.9K
01:25Renal Drug Excretion: Tubular Reabsorption
340
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
340
01:17Pore Transport and Ion-Pair Transport
653
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
653
01:28Renal Drug Excretion: Tubular Secretion
363
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
363
01:11Renal Failure: Dose Adjustments
164
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
164